On August 19, 2019 Immunicom, Inc., a medical technology company reported that it has been awarded FDA Breakthrough Device Designation for its non-pharmaceutical solution for treating stage IV metastatic cancer, hosted its 1st Annual Global Immunopheresis Clinical Conference which began on July 31st (Press release, Immunicom, AUG 19, 2019, View Source [SID1234538869]). This event provided a forum for oncology clinical leaders to meet, discuss and learn about Immunicom’s novel, cutting-edge immunotherapy − Immunopheresis.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference was a collaborative event involving Immunicom’s global partners and focused on therapeutic apheresis as a viable clinical approach in oncology that potentially represents a less-costly innovation than currently-available therapies with the promise to enhance patient care and quality of life.

"Immunicom was extremely pleased to host such accomplished clinicians and thought leaders to our 1st Annual Global Immunopheresis Clinical Conference. Clearly, their collective interest in and enthusiasm for this potentially transformational therapy fueled the robust discussions that took place throughout the conference," said Amir Jafri, founder and CEO of Immunicom.

Immunicom plans to expand this conference series and other discussion opportunities in the future to include more participants and foster the exploration of new treatment boundaries in oncology. For more information about the event, please refer to the conference website.